PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29352988-5 2018 Among the upregulated genes, MAPK3, PRKCZ and STAT3, STAT3 presented a higher level of upregulation in the DOX-treated CD44+/high/CD24-/low/ALDH+ BCSCs-like subset. Doxorubicin 107-110 mitogen-activated protein kinase 3 Homo sapiens 29-34 31377057-2 2019 Here, we identified the regulation of mammalian target of rapamycin complex1 (mTORC1) by TGF-beta via extracellular signal-regulated kinase-1/2 (ERK1/2) in the Adriamycin (ADR)-induced murine model of focal segmental glomerulosclerosis. Doxorubicin 160-170 mitogen-activated protein kinase 3 Homo sapiens 145-151 31356549-9 2019 Further study indicated that curdione decreased DOX-induced phosphorylation of extracellular signal-regulated kinase1/2 (Erk1/2) and c-Jun-N-terminal kinase and activated nuclear factor-erythroid 2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) signal pathway. Doxorubicin 48-51 mitogen-activated protein kinase 3 Homo sapiens 121-127 29795329-6 2018 Simvastatin and doxorubicin suppress the prosurvival ERK1/2 pathway in a Ca2+-independent and Ca2+-dependent manner, respectively. Doxorubicin 16-27 mitogen-activated protein kinase 3 Homo sapiens 53-59 29574069-10 2018 It is important to note that the forskolin-induced potentiation of sensitivity to doxorubicin is accompanied by a strong inhibition of ERK1/2 phosphorylation, is mimicked by ERK inhibitor PD98059 and is prevented by pre-treatment with Protein Kinase A (PKA) and adenylate cyclase inhibitors. Doxorubicin 82-93 mitogen-activated protein kinase 3 Homo sapiens 135-141 30939040-0 2019 miR-132 Regulates Adriamycin Resistance in Colorectal Cancer Cells Through Targeting Extracellular Signal-Regulated Kinase 1. Doxorubicin 18-28 mitogen-activated protein kinase 3 Homo sapiens 85-124 30939040-13 2019 Conclusions: miR-132 reduction and ERK1 elevation are related to ADM resistance in CRC cells. Doxorubicin 65-68 mitogen-activated protein kinase 3 Homo sapiens 35-39 27585662-10 2017 The protective action of Growth Hormone towards the effects of Doxorubicin may be mediated by ERK1/2 activation, while the pro-apoptotic effects of Cisplatin may be mediated by protein kinase C delta inhibition. Doxorubicin 63-74 mitogen-activated protein kinase 3 Homo sapiens 94-100 28295305-0 2018 Mitochondrial ROS-induced ERK1/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity. Doxorubicin 98-109 mitogen-activated protein kinase 3 Homo sapiens 26-32 28295305-5 2018 We found that MAPK signaling pathways, especially ERK1/2, participated in modulating AT1 R gene expression through DOX-induced mitochondrial ROS release. Doxorubicin 115-118 mitogen-activated protein kinase 3 Homo sapiens 14-18 28295305-5 2018 We found that MAPK signaling pathways, especially ERK1/2, participated in modulating AT1 R gene expression through DOX-induced mitochondrial ROS release. Doxorubicin 115-118 mitogen-activated protein kinase 3 Homo sapiens 50-56 28627650-8 2017 We further demonstrated that the inhibitory effects of DSW on doxorubicin-induced EMT appeared to be mediated by inhibition of the ERK1/2, p38 MAPK and PI3K/AKT signaling pathways. Doxorubicin 62-73 mitogen-activated protein kinase 3 Homo sapiens 131-137 28328292-8 2018 PD98059, the ERK1/2 inhibitor, attenuated IL-6 induced proliferation and synergistically increased the Dox sensitivity of si-IL-6 transfected ACHN cells. Doxorubicin 103-106 mitogen-activated protein kinase 3 Homo sapiens 13-19 29061787-7 2017 DOX induced the overexpression of MDR1 mRNA and increased the phosphorylation of Akt, ERK1/2, p38 MAPK and JNK. Doxorubicin 0-3 mitogen-activated protein kinase 3 Homo sapiens 86-92 29061787-7 2017 DOX induced the overexpression of MDR1 mRNA and increased the phosphorylation of Akt, ERK1/2, p38 MAPK and JNK. Doxorubicin 0-3 mitogen-activated protein kinase 3 Homo sapiens 98-102 27649518-6 2017 Dox and AD198 increased activation of AKT, ERK1/2, and p38 MAPK signaling pathways in tested OSCC cells by dose-dependent manner. Doxorubicin 0-3 mitogen-activated protein kinase 3 Homo sapiens 43-49 27649518-6 2017 Dox and AD198 increased activation of AKT, ERK1/2, and p38 MAPK signaling pathways in tested OSCC cells by dose-dependent manner. Doxorubicin 0-3 mitogen-activated protein kinase 3 Homo sapiens 59-63 27649518-8 2017 Inhibition of PI3K/AKT reduced Dox- and AD198-induced activation of ERK1/2 and further increased Dox- and AD198-induced phosphorylation of p38 MAPK in OSCC. Doxorubicin 31-34 mitogen-activated protein kinase 3 Homo sapiens 68-74 28218042-12 2017 Moreover, synergistic cytotoxicity of doxorubicin with cucurbitacin B is mediated by B-cell chronic lymphocytic leukemia/lymphoma 2 family proteins, survivin, and reactive oxygen species and modulated by Janus kinase 2/signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2 in anaplastic thyroid carcinoma cells. Doxorubicin 38-49 mitogen-activated protein kinase 3 Homo sapiens 274-315 28476801-12 2017 CONCLUSION: AzaC significantly increases the sensitivity of MCF7 cells to Dox via activation of ERK1/2, P53, BAX and caspase-3. Doxorubicin 74-77 mitogen-activated protein kinase 3 Homo sapiens 96-102 28098907-5 2017 We found that ADM monotherapy treatment notably upregulated the activity of extracellular signal-regulated kinase ERK1 and ERK2 (ERK1/2), but when combined with YS-1, the p-ERK1/2 level was reduced; then inhibited the Ras/Raf/MEK pathway. Doxorubicin 14-17 mitogen-activated protein kinase 3 Homo sapiens 114-118 26459009-0 2015 Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines. Doxorubicin 122-133 mitogen-activated protein kinase 3 Homo sapiens 34-40 27754360-11 2016 We showed that Rack1 regulated P-gp activity, which was necessary for adriamycin-induced P-gp-mediated phosphorylation of Anxa2 and Erk1/2. Doxorubicin 70-80 mitogen-activated protein kinase 3 Homo sapiens 132-138 27510278-8 2016 In addition, quantitative analysis of the time course of both ERK1/2 and Bcl-2 in doxorubicin (DOX)-treated MCF-7/WT cells confirmed these findings. Doxorubicin 82-93 mitogen-activated protein kinase 3 Homo sapiens 62-68 27510278-8 2016 In addition, quantitative analysis of the time course of both ERK1/2 and Bcl-2 in doxorubicin (DOX)-treated MCF-7/WT cells confirmed these findings. Doxorubicin 95-98 mitogen-activated protein kinase 3 Homo sapiens 62-68 26969380-0 2016 Sinapine reverses multi-drug resistance in MCF-7/dox cancer cells by downregulating FGFR4/FRS2alpha-ERK1/2 pathway-mediated NF-kappaB activation. Doxorubicin 49-52 mitogen-activated protein kinase 3 Homo sapiens 100-106 26658818-7 2015 Further studies with application of iNOS inhibitor and ERK1/2 kinase inhibitor indicated that the inhibitory effects of MA on DOX-induced apoptosis and inflammation might be mediated by the suppression of the activation of cleaved caspase-3, ERK1/2 pathways, NF-kappaB p65 and NO production. Doxorubicin 126-129 mitogen-activated protein kinase 3 Homo sapiens 55-61 26658818-7 2015 Further studies with application of iNOS inhibitor and ERK1/2 kinase inhibitor indicated that the inhibitory effects of MA on DOX-induced apoptosis and inflammation might be mediated by the suppression of the activation of cleaved caspase-3, ERK1/2 pathways, NF-kappaB p65 and NO production. Doxorubicin 126-129 mitogen-activated protein kinase 3 Homo sapiens 242-248 26505786-9 2016 In addition, curcumin exposure along with 5-FU or DOX inhibited cell proliferation through the downregulation of EGFR-ERK1/2 signaling molecules. Doxorubicin 50-53 mitogen-activated protein kinase 3 Homo sapiens 118-124 26299281-0 2015 Hydrogen sulfide attenuates doxorubicin-induced cardiotoxicity by inhibiting reactive oxygen species-activated extracellular signal-regulated kinase 1/2 in H9c2 cardiac myocytes. Doxorubicin 28-39 mitogen-activated protein kinase 3 Homo sapiens 111-150 26299281-3 2015 Therefore, the aim of the present study was to investigate whether the extracellular signal-regulated kinase (ERK) 1/2 signaling pathway is involved in the cardioprotection of H2S against DOX-induced cardiotoxicity. Doxorubicin 188-191 mitogen-activated protein kinase 3 Homo sapiens 71-118 26299281-5 2015 Exposure of H9c2 cardiac myocytes to DOX upregulated the expression levels of phosphorylated ERK1/2, which had been reduced by pretreatment with NaHS or N-acetyl-L-cysteine, a ROS scavenger. Doxorubicin 37-40 mitogen-activated protein kinase 3 Homo sapiens 93-99 26299281-8 2015 In conclusion, these findings indicate that H2S attenuates DOX-induced cardiotoxicity by inhibiting ROS-mediated activation of ERK1/2 in H9c2 cardiac myocytes. Doxorubicin 59-62 mitogen-activated protein kinase 3 Homo sapiens 127-133 26459009-14 2015 Non- and mildly-toxic doses of As2O3 reduced MDR to DOX through Ras/p-ERK1/2 signaling. Doxorubicin 52-55 mitogen-activated protein kinase 3 Homo sapiens 70-76 23965518-5 2013 ERK1/2 related p53 activation, but not reactive oxygen species, was responsible for Doxorubicin induced caspase-3 cleavage. Doxorubicin 84-95 mitogen-activated protein kinase 3 Homo sapiens 0-6 26340617-9 2015 Remarkably, Pi/doxorubicin combination-induced cytotoxicity was dynamically accompanied by profound changes in Erk1/2 and Stat3 protein and phosphorylation levels. Doxorubicin 15-26 mitogen-activated protein kinase 3 Homo sapiens 111-117 25968898-3 2015 We, herein, demonstrate that Wnt/beta-catenin signal pathway is constitutively activated in Doxorubicin-induced MDR cancer cells, in which nuclear beta -catenin specifically interacts with the transcriptional coactivator CBP in a MEK(1/2)/ERK(1/2) signal-dependent manner. Doxorubicin 92-103 mitogen-activated protein kinase 3 Homo sapiens 239-246 23877402-6 2013 Both PDOX and DOX significantly decreased p-ERK1/2, increased ROS generation, reduced mitochondrial membrane potential, caused mitochondrial swelling and arrested the cell cycle at the G2/S phase, and these effects were more pronounced for PDOX than for DOX. Doxorubicin 6-9 mitogen-activated protein kinase 3 Homo sapiens 44-50 23877402-6 2013 Both PDOX and DOX significantly decreased p-ERK1/2, increased ROS generation, reduced mitochondrial membrane potential, caused mitochondrial swelling and arrested the cell cycle at the G2/S phase, and these effects were more pronounced for PDOX than for DOX. Doxorubicin 14-17 mitogen-activated protein kinase 3 Homo sapiens 44-50 23877402-7 2013 PDOX and DOX have different mechanisms of action, particularly the mitochondria-centered intrinsic apoptosis involving reactive oxidative stress and the ERK1/2 signaling pathway. Doxorubicin 1-4 mitogen-activated protein kinase 3 Homo sapiens 153-159 22674530-9 2013 Moreover, the doxorubicin-induced cytotoxicity was associated with ERK1/2 pathway inhibition in response to Pi. Doxorubicin 14-25 mitogen-activated protein kinase 3 Homo sapiens 67-73 23232767-6 2013 Western blotting revealed that, following exposure to doxorubicin, YAP-overexpressing cells exhibited decreased cleaved PARP, increased phosphorylation of Akt and ERK1/2, and elevated Bcl-xL expression in comparison to the vector control. Doxorubicin 54-65 mitogen-activated protein kinase 3 Homo sapiens 175-181 22282250-0 2012 Involvement of MMP-2 in adriamycin resistance dependent on ERK1/2 signal pathway in human osteosarcoma MG-63 cells. Doxorubicin 24-34 mitogen-activated protein kinase 3 Homo sapiens 59-65 22282250-3 2012 To determine the relationship between MMP-2 and the ERK1/2 signal pathway, we established an adriamycin (ADM)-induced MG-63 (ADM-MG-63) cell line. Doxorubicin 93-103 mitogen-activated protein kinase 3 Homo sapiens 52-58 23493035-3 2012 In this study, cytotoxicity and the expression of Erk1/2 and phospho-ERK was compared in MDA-MB-231 (ER-) and MCF-7 (ER+) cell lines after treatment with doxorubicin (DOX) or docetaxel (DOCT). Doxorubicin 154-165 mitogen-activated protein kinase 3 Homo sapiens 50-56 23493035-9 2012 In MDA-MB-231 cells the expression of ERK1/2 and phospho-ERK was decreased after DOX treatment in a dose-dependent manner. Doxorubicin 81-84 mitogen-activated protein kinase 3 Homo sapiens 38-44 23493035-10 2012 In contrast in MCF-7 cells the expression of ERK1/2 and phospho-ERK was increased after DOX treatment. Doxorubicin 88-91 mitogen-activated protein kinase 3 Homo sapiens 45-51 23133614-8 2012 Moreover, the enhanced doxorubicin resistance is independent of DNA damage related p53 pathway, but at least partially through the ERK1/2 pathway. Doxorubicin 23-34 mitogen-activated protein kinase 3 Homo sapiens 131-137 23133614-9 2012 Together, our study revealed that silencing PrP in MDA-MB-435 breast cancer cells results in very different responses to various cytotoxic stimuli and ERK1/2 signaling pathway is involved in PrP silencing caused resistance to doxorubicin. Doxorubicin 226-237 mitogen-activated protein kinase 3 Homo sapiens 151-157 18974122-8 2008 The phosphorylation of Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) is elevated in Cas-overexpressing cells treated with Adriamycin, whereas expression of the proapoptotic protein Bak is decreased. Doxorubicin 135-145 mitogen-activated protein kinase 3 Homo sapiens 74-80 20428768-0 2010 Low doses of ionizing radiation suppress doxorubicin-induced senescence-like phenotypes by activation of ERK1/2 and suppression of p38 kinase in MCF7 human breast cancer cells. Doxorubicin 41-52 mitogen-activated protein kinase 3 Homo sapiens 105-111 20428768-10 2010 The results thus suggest that low doses of radiation suppress doxorubicin-induced replicative senescence through the inhibition of p38-dependent phosphorylation of p53 and by activation of ERK1/2, without genomic damage. Doxorubicin 62-73 mitogen-activated protein kinase 3 Homo sapiens 189-195 19417026-1 2009 PURPOSE: Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) dephosphorylates mitogen-activated protein kinase [extracellular signal-regulated kinase (ERK), c-Jun NH(2)-terminal kinase (JNK), and p38], mediates breast cancer chemoresistance, and is repressible by doxorubicin in breast cancer cells. Doxorubicin 274-285 mitogen-activated protein kinase 3 Homo sapiens 43-47 19417026-3 2009 EXPERIMENTAL DESIGN: Doxorubicin effects on MKP-1, phospho-ERK1/2 (p-ERK1/2), phospho-JNK (p-JNK), and phospho-p38 were assayed in a panel of human breast cancer cells by Western blot and in human breast cancer were assayed ex vivo by immunohistochemistry (n = 50). Doxorubicin 21-32 mitogen-activated protein kinase 3 Homo sapiens 59-65 19417026-3 2009 EXPERIMENTAL DESIGN: Doxorubicin effects on MKP-1, phospho-ERK1/2 (p-ERK1/2), phospho-JNK (p-JNK), and phospho-p38 were assayed in a panel of human breast cancer cells by Western blot and in human breast cancer were assayed ex vivo by immunohistochemistry (n = 50). Doxorubicin 21-32 mitogen-activated protein kinase 3 Homo sapiens 69-75 19417026-7 2009 Similar to what was observed in breast cancer cell lines, ex vivo exposure of breast tumors to doxorubicin down-regulated MKP-1, and up-regulated p-ERK1/2 and p-JNK, in the majority of cases. Doxorubicin 95-106 mitogen-activated protein kinase 3 Homo sapiens 148-154 21790999-8 2011 ERK1/2 activation induced by DOX was suppressed by sorafenib. Doxorubicin 29-32 mitogen-activated protein kinase 3 Homo sapiens 0-6 21314951-9 2011 Additionally, sFZD7 altered the levels of phosphorylated AKT and ERK1/2 induced by doxorubicin treatment in vitro, suggesting that several critical pathways are involved in the chemosensitizing effect of sFZD7. Doxorubicin 83-94 mitogen-activated protein kinase 3 Homo sapiens 65-71 21159167-0 2010 Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Doxorubicin 65-76 mitogen-activated protein kinase 3 Homo sapiens 12-16 21159167-2 2010 Here we show using human MM lines that Dox activates extracellular signal-regulated kinases (ERK1 and 2), causally linked to increased expression of ABC transporter genes, decreased accumulation of Dox, and enhanced MM growth. Doxorubicin 39-42 mitogen-activated protein kinase 3 Homo sapiens 93-103 21159167-2 2010 Here we show using human MM lines that Dox activates extracellular signal-regulated kinases (ERK1 and 2), causally linked to increased expression of ABC transporter genes, decreased accumulation of Dox, and enhanced MM growth. Doxorubicin 198-201 mitogen-activated protein kinase 3 Homo sapiens 93-103 21159167-3 2010 Using the MEK1/2 inhibitor, U0126 and stably transfected shERK1 and shERK2 MM cell lines, we show that inhibition of both ERK1 and 2 sensitizes MM cells to Dox. Doxorubicin 156-159 mitogen-activated protein kinase 3 Homo sapiens 122-132 19913499-4 2010 Concomitantly, PFT-alpha treatment prevented down regulation of ERK1/2 activation by either antibody or doxorubicin. Doxorubicin 104-115 mitogen-activated protein kinase 3 Homo sapiens 64-70 18974122-10 2008 Based on these data, we propose that Cas activates growth and survival pathways regulated by c-Src, Akt, and ERK1/2 that lead to the inhibition of mitochondrial-mediated apoptosis in the presence of Adriamycin. Doxorubicin 199-209 mitogen-activated protein kinase 3 Homo sapiens 109-115 18594523-7 2008 Evaluation of signalling pathways showed that MnSOD siRNA enhanced doxorubicin- and paclitaxel-induced phosphorylation of extracellular signal-regulated kinase 1/2. Doxorubicin 67-78 mitogen-activated protein kinase 3 Homo sapiens 122-163 18164246-0 2008 The volume-sensitive chloride channel inhibitors prevent both contractile dysfunction and apoptosis induced by doxorubicin through PI3kinase, Akt and Erk 1/2. Doxorubicin 111-122 mitogen-activated protein kinase 3 Homo sapiens 150-157 18164246-8 2008 Thus, I(Cl,vol) inhibitors prevent doxorubicin-induced apoptosis and subsequent contractile dysfunction through PI(3)kinase/Akt and Erk 1/2. Doxorubicin 35-46 mitogen-activated protein kinase 3 Homo sapiens 132-139 17581316-1 2007 We previously demonstrated the simultaneous induction of urokinase-type plasminogen activator and interleukin-8, a CXC chemokine, in doxorubicin-treated human NCI-H69 small cell lung cancer cells in which extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase might be involved. Doxorubicin 133-144 mitogen-activated protein kinase 3 Homo sapiens 205-246 15494689-1 2004 AIM: To understand the biochemical basis of cell sensitivity to cytotoxic effect of doxorubicine (DOX), we investigated signaling cascades mediated by c-Jun N-terminal protein kinases (JNK1/2), p38 mitogen-activated protein kinases (MAPK), extracellular signal-regulated protein kinase (ERK1/2) and protein kinase B/Akt in both DOX-sensitive BL41 and the DOX-resistant DG75 Burkitt"s lymphoma (BL) cell lines. Doxorubicin 84-96 mitogen-activated protein kinase 3 Homo sapiens 287-293 17513610-10 2007 Moreover, GSTP1 suppression decreased the activation of extracellular signal-regulated kinase 1/2, which is induced by cisplatin and doxorubicin. Doxorubicin 133-144 mitogen-activated protein kinase 3 Homo sapiens 56-97 17513610-11 2007 Taken together, these findings show that GSTP1 contributes to doxorubicin and cisplatin resistance in osteosarcoma, which may be mediated in part by the activation of extracellular signal-regulated kinase 1/2. Doxorubicin 62-73 mitogen-activated protein kinase 3 Homo sapiens 167-208 15557793-0 2004 Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells. Doxorubicin 44-55 mitogen-activated protein kinase 3 Homo sapiens 15-21 34565287-0 2021 Silencing aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing beta-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway. Doxorubicin 121-132 mitogen-activated protein kinase 3 Homo sapiens 253-259 8913269-1 1996 We studied the activation of c-jun N-terminal kinase 1 (JNK 1) and extracellular signal-regulated kinases 1 and 2 (ERK 1/2) of mitogen-activated protein kinase (MAPK) family by adriamycin (ADR) in the human T cell leukemia line, H9. Doxorubicin 177-187 mitogen-activated protein kinase 3 Homo sapiens 115-122 8913269-1 1996 We studied the activation of c-jun N-terminal kinase 1 (JNK 1) and extracellular signal-regulated kinases 1 and 2 (ERK 1/2) of mitogen-activated protein kinase (MAPK) family by adriamycin (ADR) in the human T cell leukemia line, H9. Doxorubicin 177-187 mitogen-activated protein kinase 3 Homo sapiens 161-165 34749347-0 2021 DOX-loaded silver nanotriangles and photothermal therapy exert a synergistic antibreast cancer effect via ROS/ERK1/2 signaling pathway. Doxorubicin 0-3 mitogen-activated protein kinase 3 Homo sapiens 110-116 31843629-0 2020 Parameritannin A-2 from Urceola huaitingii enhances doxorubicin-induced mitochondria-dependent apoptosis by inhibiting the PI3K/Akt, ERK1/2 and p38 pathways in gastric cancer cells. Doxorubicin 52-63 mitogen-activated protein kinase 3 Homo sapiens 133-139 34830320-9 2021 AKT and ERK1/2 expression were also increased in DRM cells with the advancement of resistance to doxorubicin. Doxorubicin 97-108 mitogen-activated protein kinase 3 Homo sapiens 8-14 35395977-7 2022 Compared with DOX alone treatment group, the expressions of p-MEK and p-ERK1/2 in DOX+ML-098 combined treatment group were increased, and the levels of cleaved caspase-3,9 in H929 cells were decreased (P<0.05). Doxorubicin 14-17 mitogen-activated protein kinase 3 Homo sapiens 72-78 35395977-7 2022 Compared with DOX alone treatment group, the expressions of p-MEK and p-ERK1/2 in DOX+ML-098 combined treatment group were increased, and the levels of cleaved caspase-3,9 in H929 cells were decreased (P<0.05). Doxorubicin 82-85 mitogen-activated protein kinase 3 Homo sapiens 72-78 33204396-14 2020 We found seven putative genes predicted to be modulated by Rsv in the context of Doxo treatment: CCND1, CDH1, ESR1, HSP90AA1, MAPK3, PTPN11, and RPS6KB1. Doxorubicin 81-85 mitogen-activated protein kinase 3 Homo sapiens 126-131 32722178-0 2020 The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. Doxorubicin 72-83 mitogen-activated protein kinase 3 Homo sapiens 134-140 32722178-4 2020 In doxorubicin-treated H9c2 cardiomyoblasts, the long-lasting cardioprotection is mediated by activation of the Ras/Raf/Mek/Erk (extracellular signal-regulated kinase 1,2) signaling pathway and requires Stat3 (signal transducer and activator of transcription 3) activation. Doxorubicin 3-14 mitogen-activated protein kinase 3 Homo sapiens 129-168 34471052-6 2021 Furthermore, Western blotting analyses showed that treatment with rhinacanthin-C (3-28 microM) for 24 h significantly decreased the expression levels of the phosphorylated forms of MAPK proteins (i.e., extracellular signal regulated protein kinase 1/2 (ERK1/2), c-Jun N-terminal kinases (JNK) and p38), Akt, GSK-3beta and Nrf2 proteins in MCF-7/DOX cells. Doxorubicin 345-348 mitogen-activated protein kinase 3 Homo sapiens 181-185 32562081-6 2021 RESULTS: We observed that MSM itself induces apoptosis in EC cell lines, and pre-treatment with MSM for 24 h increases the sensitivity of EC cells to DOX-induced apoptosis and DNA damage and that effect might be regulated by p42/44 (Erk1/2) MAPK and Akt (protein kinase B). Doxorubicin 150-153 mitogen-activated protein kinase 3 Homo sapiens 233-239 31843629-7 2020 Moreover, PA-2 attenuates the DOX-induced activation of Akt, ERK1/2 and p38 signaling pathways, providing a molecular mechanism for the synergistic effects of DOX and PA-2 in the induction of apoptosis. Doxorubicin 30-33 mitogen-activated protein kinase 3 Homo sapiens 61-67 31843629-7 2020 Moreover, PA-2 attenuates the DOX-induced activation of Akt, ERK1/2 and p38 signaling pathways, providing a molecular mechanism for the synergistic effects of DOX and PA-2 in the induction of apoptosis. Doxorubicin 159-162 mitogen-activated protein kinase 3 Homo sapiens 61-67 31843629-8 2020 In conclusion, our studies demonstrate that PA-2 and DOX synergistically induce mitochondria-dependent apoptosis as PA-2 inhibits the PI3K/Akt, ERK1/2 and p38 pathways in HGC27 cells. Doxorubicin 53-56 mitogen-activated protein kinase 3 Homo sapiens 144-150 32277647-0 2020 Phloretin flavonoid exhibits selective antiproliferative activity in doxorubicin-resistant gastric cancer cells by inducing autophagy, inhibiting cell migration and invasion, cell cycle arrest and targeting ERK1/2 MAP pathway. Doxorubicin 69-80 mitogen-activated protein kinase 3 Homo sapiens 207-213